Clinical Trials List
2021-04-01 - 2024-12-31
Phase I
Recruiting5
ICD-10C45.9
Mesothelioma, unspecified
ICD-10C79.9
Secondary malignant neoplasm of unspecified site
ICD-10C7A.00
Malignant carcinoid tumor of unspecified site
ICD-10C7A.094
Malignant carcinoid tumor of the foregut NOS
ICD-10C7A.095
Malignant carcinoid tumor of the midgut NOS
ICD-10C7A.096
Malignant carcinoid tumor of the hindgut NOS
ICD-10C7A.1
Malignant poorly differentiated neuroendocrine tumors
ICD-10C7A.8
Other malignant neuroendocrine tumors
ICD-10C7B.00
Secondary carcinoid tumors, unspecified site
ICD-10C80.1
Malignant (primary) neoplasm, unspecified
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9199.1
Malignant neoplasm of unspecified site (primary) (secondary)
-
Trial Applicant
COVANCE TAIWAN SERVICES LIMITED
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
Co-Principal Investigator
- Jen-Shi Chen Division of Hematology & Oncology
- Ming-Mo Hou Division of Hematology & Oncology
- 黃文冠 Division of Hematology & Oncology
- Wen-Chi Chou Division of Hematology & Oncology
- Chia-Hsun Hsieh Division of Hematology & Oncology
- Mengting Peng Division of Hematology & Oncology
- Tsai-Sheng Yang Division of Hematology & Oncology
- Po-Jung Su Division of Hematology & Oncology
- Yung-Chia Kao Division of Hematology & Oncology
- 呂嘉偉 Division of Radiology
- Wen-Chi Shen Division of Hematology & Oncology
- 吳教恩 Division of Hematology & Oncology
- Pei-Wei Huang Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 徐偉勛 Division of Hematology & Oncology
- Jih-Hsiang Lee Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ching Yun Hsieh Division of Hematology & Oncology
- Chen-Yuan Lin Division of Hematology & Oncology
- Chang-Fang Chiu Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 曹朝榮, 黃文聰, 陳昭勳, 林建良, 陳尚文, 林正耀, 蕭聖諺, 高婉真 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Shang-Hung Chen 國家衛生研究院
- Shang-Yin Wu Division of Hematology & Oncology
- Chia-Jui Yen Division of Hematology & Oncology
- Jui-Hung Tsai Division of Hematology & Oncology
- Wu-Chou Su Division of Hematology & Oncology
- Wei-Pang Chung Division of Hematology & Oncology
- Peng-Chan Lin Division of Hematology & Oncology
- 黃盈慈 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
50 participants
-
Global
350 participants
